Axsome Therapeutics Secures $570M Loan with Blackstone

Axsome Therapeutics ( (AXSM) ) has issued an announcement.

On May 8, 2025, Axsome Therapeutics entered into a $570 million loan agreement with Blackstone, replacing its previous loan with Hercules Capital. This agreement, which includes a term loan and revolving credit facility, is expected to reduce interest expenses and support Axsome’s growth and profitability goals. The company also completed a private placement of common stock with Blackstone, raising approximately $15 million. These financial moves aim to enhance Axsome’s operational and financial agility, supporting its mission to improve patient outcomes in CNS disorders.

The most recent analyst rating on (AXSM) stock is a Buy with a $175.00 price target. To see the full list of analyst forecasts on Axsome Therapeutics stock, see the AXSM Stock Forecast page.

Spark’s Take on AXSM Stock

According to Spark, TipRanks’ AI Analyst, AXSM is a Neutral.

Axsome Therapeutics shows promising revenue growth and product development, yet its financial stability is hindered by ongoing losses and high leverage. The positive earnings call outlook is tempered by regulatory challenges and profitability issues. Mixed technical indicators further suggest caution in the short term. Overall, while the growth potential is significant, financial and market risks warrant a conservative stock score.

To see Spark’s full report on AXSM stock, click here.

More about Axsome Therapeutics

Axsome Therapeutics is a biopharmaceutical company focused on treating central nervous system (CNS) disorders. The company develops products with novel mechanisms of action to address major depressive disorder, excessive daytime sleepiness, narcolepsy, obstructive sleep apnea, and migraine, among other neurological and psychiatric conditions.

Average Trading Volume: 777,670

Technical Sentiment Signal: Buy

Current Market Cap: $5.42B

For detailed information about AXSM stock, go to TipRanks’ Stock Analysis page.